| Sunday June 23, 2024 |
| 11:00 | Registration |
|
| 13:00 | Welcome Address by NMCS Co-Chairs |
Dr Patrick BURKE (ENLAZA THERAPEUTICS, San Diego, CA, United States)
Dr Rheem A. TOTAH (UNIVERSITY OF WASHINGTON, Lake Forest Park, WA, United States) |
| 13:15 | Plenary Opening Session: Recent Advances and Emerging Opportunities in Medicinal Chemistry
Sponsored by Gilead |
|
| Session Chair |
Dr Paul SCOLA
(BRISTOL MYERS SQUIBB, Cambridge, MA, United States) |
| 13:15 | Introduction |
|
| 13:20 | A Synopsis of the Impact of Small Molecules on Human Health and Longevity (PL01) |
Dr Nicholas MEANWELL
(BARUCH S. BLUMBERG INSTITUE AND UNIVERSITY OF MICHIGAN, Wallingford, CT, United States) |
| 14:05 | Rediscovering Macrocycles as a Modality in Drug Discovery (PL02) |
Dr Katerina LEFTHERIS
(VILYA, INC., SF Bay Area, CA, United States) |
| 14:50 | Coffee Break & Exhibition |
|
| 15:20 | Inhibition of Protein Aggregation and the Development of AKV9 (formerly NU-9) for Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases (PL03) |
Prof. Richard B. SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, IL, United States) |
| 16:05 | Flash Poster Session 1 |
|
| Session Chair |
Dr Juhienah KHALAF
(INIMMUNE CORPORATION, Missoula, MT, United States) |
| 16:05 | Flash Poster presentations |
|
| 16:35 | Poster Session 1 |
|
| 18:00 | Welcome Reception |
|
| 19:00 | End of the day |
|
| Monday June 24, 2024 |
| 08:30 | Session 1: Advances in Protein Proximity, Induction and Degradation |
|
| Session Chairs |
Dr Timothy HEFFRON (GENENTECH, South San Francisco, CA, United States)
Dr Elisia VILLEMURE (GENENTECH, South San Francisco, CA, United States) |
| 08:30 | Introduction |
|
| 08:35 | Ubiquitin Ligases and Molecular Glue Degraders (IL01) |
Prof. Ning ZHENG
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States) |
| 09:05 | Informatics Accelerated CRBN Glue Lead Discovery (IL02) |
Dr Lingling SHEN
(NOVARTIS, Belmont, United States) |
| 09:35 | Design and Optimisation of Molecular Glue Degraders (IL03) |
Dr Magnus WALTER
(MONTE ROSA THERAPEUTICS, Basel, Switzerland) |
| 10:05 | Coffee Break & Exhibition |
|
| 10:35 | Stabilization of 14-3-3 Protein-Protein Interactions with Covalent Molecular Glues (IL04) |
Dr Markella KONSTANTINIDOU
(UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, United States) |
| 11:05 | Hold and Kill: RIPTAC™ Therapeutics Present a Novel Mechanism to Conquer Cancer (IL05) |
Dr Kat KAYSER-BRICKER
(HALDA THERAPEUTICS, New Haven, CT, United States) |
| 11:35 | Magnet Biomedicine's TrueGlue Platform: A Systematic Approach Towards the Discovery of Molecular Glues for Therapeutic Intervention (IL06) |
Dr Matthew HAYWARD
(MAGNET BIOMEDICINE, Boston, MA, United States) |
| 12:05 | Lunch & Exhibition |
|
| 12:15 | Optional Schrodinger Workshop
Prioritizing DLK Inhibitors for Potency, Selectivity, and Brain-penetration: a Digital Chemistry Design Challenge |
|
| 13:20 | Session 2: Chemical Perturbation of Methylation towards Anticancer Drug Discovery |
|
| Session Chairs |
Prof. Rong HUANG (PURDUE UNIVERSITY, West Lafayette, IN, United States)
Dr Rheem A. TOTAH (UNIVERSITY OF WASHINGTON, Lake Forest Park, WA, United States) |
| 13:20 | Introduction |
|
| 13:25 | Discovery of Novel Small-molecule Degraders for Protein Methyltransferases and Development of New Approaches to Target Undruggable Proteins (IL07) |
Prof. Jian JIN
(ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY, United States) |
| 13:55 | Development of Potent and Specific Inhibitors for Methyltransferases (IL08) |
Prof. Rong HUANG
(PURDUE UNIVERSITY, West Lafayette, IN, United States) |
| 14:25 | Discovery of MRTX1719, a Synthetic Lethal Approach for the Treatment of MTAP-Deleted Cancers (IL09) |
Dr Matthew MARX
(MIRATI THERAPEUTICS INC, San Diego, United States) |
| 14:55 | Coffee Break & Exhibition |
|
| 15:25 | Session 3: Infectious Disease Drug Discovery |
|
| Session Chair |
Dr Lori FERRINS
(NORTHEASTERN UNIVERSITY, Boston, MA, United States) |
| 15:25 | Introduction |
|
| 15:30 | Targeting Infectious Diseases with Kinase Inhibitors (IL10) |
Dr David DREWRY
(UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC, United States) |
| 16:00 | Development of Quinazolin-4-Ones that Show Efficacy in Lethal Murine Models of Venezuelan and Eastern Equine Encephalitis (IL11) |
Dr Jennifer GOLDEN
(UNIVERSITY OF WISCONSIN, Madison, WI, United States) |
| 16:30 | Invention of MK-7602: an Antimalarial Drug Discovery Collaboration (IL12) |
Dr John A MCCAULEY
(MERCK, West Point, United States) |
| 17:00 | Flash Poster Session 2 |
|
| Session Chair |
Dr Juhienah KHALAF
(INIMMUNE CORPORATION, Missoula, MT, United States) |
| 17:00 | Flash Poster presentations |
|
| 17:30 | Poster Session 2 |
|
| 19:00 | End of the day |
|
| Tuesday June 25, 2024 |
| 08:30 | Session 4: Targeted Drug Delivery |
|
| Session Chair |
Dr Patrick BURKE
(ENLAZA THERAPEUTICS, San Diego, CA, United States) |
| 08:30 | Introduction |
|
| 08:35 | Development of a Novel TOPO1i ADC Platform: from Concept to Pipeline Application (IL13) |
Dr Mark PETERSEN
(ZYMEWORKS, Vancouver, Canada) |
| 09:05 | Harnessing the power of ADCs by careful selection of target, linker, payload, indication, and combination partner (IL14) |
Dr Sharsti SANDALL
(PFIZER , Bothell, WA, United States) |
| 09:35 | Targeted Radionuclide Therapy: the Promise and Challenges of Short-lived Alpha-emitting Actinides (IL15) |
Dr Rebecca ABERGEL
(UNIVERSITY OF CALIFORNIA, Berkeley, CA, United States) |
| 10:05 | Coffee Break & Exhibition |
|
| 10:35 | Session 5: Non-catalytic Kinase Function and Pseudokinases as Drug Targets |
|
| Session Chair |
Prof. Robert DEVITA
(ICAHN SCHOOL OF MEDICINE AT MT. SINAI, New York, NY, United States) |
| 10:35 | Introduction |
|
| 10:40 | Targeting Functional Sites on Pseudokinase Complexes (IL16) |
Dr Arvin DAR
(MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY, United States) |
| 11:10 | Discovery of the TYK2 Pseudokinase Domain as a Drug Target (IL17) |
Dr John TOKARSKI
(BRISTOL MYERS SQUIBB, Princeton, United States) |
| 11:40 | Discovery of TAK-279, a Highly Potent and Selective TYK2 Pseudokinase Inhibitor for the Treatment of Autoimmune Diseases, through Structure-based Drug Design (IL18) |
Dr Angela TOMS WEST
(NIMBUS THERAPEUTICS, INC., Franklin, MA, United States) |
| 12:40 | Poster Prizes |
|
| 12:50 | End of AM Scientific Program |
|
| 13:00 | Optional MilliporeSigma Workshop
Title to be announced |
|
| 13:00 | Free afternoon & Excursions |
|
| 17:44 | Award Session |
|
| 17:45 | Award Dinner |
|
| 19:15 | Award Session |
|
| 19:15 | MEDI Division Award Ceremony & Lecture |
|
| 19:25 | MEDI Division Award Lecture (AL01) |
Dr Maria-Jesus BLANCO
(ATAVISTIK BIO, Cambridge, MA, United States) |
| 20:10 | Ralph F. Hirschmann Award Lecture (AL02) |
Prof. Paramjit ARORA
(NYU, New York, United States) |
| 21:05 | End of the day |
|
| Wednesday June 26, 2024 |
| 08:30 | Session 6: A Medicinal Chemist’s Toolbox |
|
| Session Chair |
Dr Nicholas MEANWELL
(BARUCH S. BLUMBERG INSTITUE AND UNIVERSITY OF MICHIGAN, Wallingford, CT, United States) |
| 08:30 | Introduction |
|
| 08:35 | Non-additivity in Drug Design (IL19) |
Dr Bernd KUHN
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| 09:05 | The Rise of Targeting Chimeras (TACs): Next-generation Medicines that Preempt Cellular Events (IL20) |
Dr Veerabahu SHANMUGASUNDARAM
(BRISTOL MYERS SQUIBB, Cambridge, MA, United States) |
| 09:35 | Kinetic Selectivity? A Missed Opportunity in Drug Discovery? (IL21) |
Prof. Peter TONGE
(STONY BROOK UNIVERSITY, Stony Brook, NY, United States) |
| 10:05 | Coffee Break & Exhibition |
|
| 10:35 | Mechanism-Based Approaches for Targeting Histone Reader Proteins (IL22) |
Prof. Marcey WATERS
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, NC, United States) |
| 11:05 | Lessons in Proteome-Wide Covalent Drug Discovery (IL23) |
Dr Benjamin HORNING
(VIVIDION THERAPEUTICS INC., San Diego, United States) |
| 11:35 | Metabolism-Driven Drug Design: Role of Metabolite Profiling and Identification in Medicinal Chemistry (IL24) |
Dr Deepak DALVIE
(CRINETICS PHARMACEUTICALS, San Diego, CA, United States) |
| 12:05 | Lunch & Exhibition |
|
| 12:15 | Optional Enzymlogic Workshop
Kinetic Selectivity: a Missed Opportunity in Drug Design? |
|
| 13:20 | Session 7: Use of Machine Learning in Drug Discovery |
|
| Session Chair |
Dr Katerina LEFTHERIS
(VILYA, INC., SF Bay Area, CA, United States) |
| 13:20 | Introduction |
|
| 13:25 | Machine Learning Guided Design of Peptide-based Antibiotics and Antivirals (IL25) |
Dr Gaurav BHARDWAJ
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States) |
| 13:55 | The Application of AI and ML to Small Molecule Drug Discovery (IL26) |
Dr Gavin HIRST
(ATOMWISE, San Francisco, CA, United States) |
| 14:25 | Driving Innovation with Machine Learning: Impact on a Pipeline of Drug Discovery Programs (IL27) |
Dr Jennifer KNIGHT
(SCHRÖDINGER, New York, NY, United States) |
| 14:55 | Coffee Break & Exhibition |
|
| 15:25 | Rapid Identification of HPGD Inhibitors Using Physics-based Machine Learning Methods (IL28) |
Dr Leela Sriram DODDA
(NIMBUS THERAPEUTICS, Boston, United States) |
| 15:55 | Artificial Intelligence in Drug Discovery – Revolution, Evolution, or Complete Nonsense (IL29) |
Dr Patrick WALTERS
(RELAY THERAPEUTICS, Cambridge, MA, United States) |
| 16:25 | Generate-make-test: AI-in-the-loop High-throughput Drug Discovery (IL30) |
Dr Matt WELBORN
(IAMBIC THERAPEUTICS, La Jolla, CA, United States) |
| 16:55 | Closing Remarks |
Dr Patrick BURKE (ENLAZA THERAPEUTICS, San Diego, CA, United States)
Dr Rheem A. TOTAH (UNIVERSITY OF WASHINGTON, Lake Forest Park, WA, United States) |
| 17:05 | End of NMCS 2024 & Departure |
|
